Nusinersen (Spinraza®) was the first disease-modifying treatment approved by EMA and FDA for SMA patients regardless of their age, SMA type, functional status, and the number of SMN2 gene copies. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.